Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial.
CEA mRNA
Colon cancer
High-risk stage II
Postoperative adjuvant chemotherapy
Uracil and tegafur plus leucovorin (UFT/LV)
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
accepted:
26
10
2023
medline:
2
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
epublish
Résumé
The goal of the current study was to identify prognostic factors for disease-free survival (DFS) and overall survival (OS) in high-risk stage II colon cancer. The subjects were patients with histologically confirmed stage II colon cancer undergoing R0 resection who met at least one of the following criteria: T4, perforation/penetration, poorly differentiated adenocarcinoma, mucinous carcinoma, and < 12 examined lymph nodes. Patients self-selected surgery alone or a 6-month oral uracil and tegafur plus leucovorin (UFT/LV) regimen. Serum CEA mRNA at ≥ 24 h after surgery and < 2 weeks after registration was also examined as a potential prognostic factor for stage II colon cancer. This study is registered with UMIN-CTR (protocol ID: UMIN000007783). 1880 were included in the analysis to identify prognostic factors for DFS and OS in patients with high-risk stage II colon cancer. In multivariate analyses, gender, depth of tumor invasion, extent of lymph node dissection, number of examined lymph nodes, and postoperative adjuvant chemotherapy (POAC) emerged as significant independent prognostic factors for DFS. Similarly, multivariate analysis showed that age, gender, depth of tumor invasion, perforation/penetration, extent of lymph node dissection, number of examined lymph nodes, and POAC were significant independent prognostic factors for OS. Univariate analyses showed no significant difference in DFS or OS for CEA mRNA-positive and mRNA-negative cases. This study showed that gender, depth of tumor invasion, extent of lymph node dissection, number of examined lymph nodes, and lack of use of POAC were significant independent prognostic factors in stage II colon cancer.
Identifiants
pubmed: 37903983
doi: 10.1007/s00384-023-04559-7
pii: 10.1007/s00384-023-04559-7
pmc: PMC10615946
doi:
Substances chimiques
Tegafur
1548R74NSZ
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
260Informations de copyright
© 2023. The Author(s).
Références
Clin Colorectal Cancer. 2015 Dec;14(4):277-80
pubmed: 26068602
BMC Cancer. 2022 Feb 15;22(1):170
pubmed: 35168560
Ann Oncol. 2012 Oct;23(10):2479-2516
pubmed: 23012255
Ann Surg. 2007 Dec;246(6):1040-6
pubmed: 18043108
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Compr Canc Netw. 2013 May 1;11(5):519-28
pubmed: 23667203
Br J Cancer. 2010 Apr 27;102(9):1327-34
pubmed: 20389297
Nat Med. 2023 Jan;29(1):127-134
pubmed: 36646802
N Engl J Med. 2003 Jul 17;349(3):247-57
pubmed: 12867608
J Am Coll Surg. 2014 Nov;219(5):1056-69
pubmed: 25440029
Ann Surg Oncol. 2014 Jun;21(6):1765-7
pubmed: 24627156
Ann Surg Oncol. 2007 Mar;14(3):1092-8
pubmed: 17200912
J Glob Oncol. 2019 Feb;5:1-19
pubmed: 30802158
Surgery. 2022 Sep;172(3):859-868
pubmed: 35864050
Br J Surg. 2007 Jan;94(1):96-105
pubmed: 17058316
Int J Clin Oncol. 2020 Jan;25(1):1-42
pubmed: 31203527
Dig Surg. 2013;30(4-6):368-74
pubmed: 24107470
J Clin Oncol. 2004 Aug 15;22(16):3408-19
pubmed: 15199089
Eur J Surg Oncol. 2023 Jul;49(7):1291-1297
pubmed: 36841695
Tech Coloproctol. 2016 Sep;20(9):647-52
pubmed: 27522597
Clin Cancer Res. 2007 Apr 15;13(8):2406-13
pubmed: 17406027
Ann Surg Oncol. 2015 Feb;22(2):528-34
pubmed: 25160735
Surgery. 2022 Jun;171(6):1473-1479
pubmed: 34862070
J Clin Oncol. 2012 Mar 20;30(9):972-9
pubmed: 22355049
J Anus Rectum Colon. 2019 Oct 30;3(4):175-195
pubmed: 31768468
J Surg Oncol. 2022 Sep;126(4):748-756
pubmed: 35698854